Xarelto Reviewers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA staff who participated in the review of Johnson & Johnson/Bayer’s oral anticoagulant rivaroxaban for prevention of stroke and systemic embolism in patients with atrial fibrillation